Patheon N.V. (NYSE:PTHN) Files An 8-K Other Events

Patheon N.V. (NYSE:PTHN) Files An 8-K Other Events

Story continues below

ITEM 8.01

Other Events.
On November 25, 2016, a subsidiary of Patheon N.V. (Patheon or
the Company) entered into a definitive agreement to acquire a
state-of-the-art active pharmaceutical ingredients (API)
manufacturing facility located in Florence, South Carolina from a
subsidiary of Hoffmann-La Roche Ltd. (Roche). to the terms and
subject to the conditions of the purchase agreement, Patheon will
acquire all of the issued and outstanding stock of Roche Carolina
Inc., a South Carolina corporation and indirect wholly-owned
subsidiary of Roche which owns the facility, for $1,000,000, plus
a payment for certain associated inventory and certain spare
parts. Roche has also agreed to provide funds for certain
accounts payable, capital expenditure and other liabilities of
the facility. Patheon also entered into a multi-year supply
arrangement with Roche to which Patheon will manufacture certain
products for Roche.
On November 28, 2016, Patheon issued a press release announcing
that it has entered into the purchase agreement and the supply
agreement described above. A copy of the press release is
attached as Exhibit 99.1 and is incorporated herein by reference.
Forward Looking Information
Patheon claims the protections of the safe-harbor for forward
looking statements contained in the Private Securities Litigation
Reform Act of 1995. The statements in this Current Report on Form
8-K that are not historical facts may be forward-looking
statements. Readers can identify these forward-looking statements
by the use of words such as expects, may, will, approximately, or
the negative version of these words or other comparable words.
Such forward looking statements are subject to various risks and
uncertainties, which could cause actual results to differ from
those indicated in these forward looking statements. For more
information concerning factors that could cause actual results to
differ materially from those conveyed in the forward-looking
statements, please refer to the Risk Factors section of the
prospectus included in the companys registration statement, in
the form last filed with the SEC.
Forward-looking statements include, but are not limited to,
statements about the benefits of the proposed acquisition, plans,
objectives, expectations and intentions, and other statements
that are not historical facts. These statements are based on
estimates, projections, beliefs, and assumptions that Patheon
believes are reasonable but are not guarantees of future events,
performance or results. Actual future events and results may
differ materially from those expressed in these forward-looking
statements as a result of a number of important factors.
Important factors that could cause actual results to differ
materially from those indicated by such forward-looking
statements include risks and uncertainties relating to the risk
that the acquisition will not be integrated successfully; the
diversion of management time on acquisition-related issues;
general worldwide economic conditions and related uncertainties;
and the effect of any changes in governmental regulations.
Patheon undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new
information, future developments or otherwise, except as required
by applicable law. Accordingly, readers should not place undue
reliance on forward-looking statements as a prediction of actual
ITEM 9.01
Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is filed as part of this report:
Exhibit Number
Press Release, dated November 28, 2016

About Patheon N.V. (NYSE:PTHN)

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments are Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment provides manufacturing and packaging for approved prescription, over the counter and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product’s development to regulatory approval and beyond, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides development and manufacturing for the biologically active component of a pharmaceutical product from early development through commercial production. It provides a range of active pharmaceutical ingredient and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing, packaging, and life cycle management.

Patheon N.V. (NYSE:PTHN) Recent Trading Information

Patheon N.V. (NYSE:PTHN) closed its last trading session down -0.24 at 26.29 with 100,968 shares trading hands.

An ad to help with our costs